Marinus Pharmaceuticals Inc

NASDAQ:MRNSUnited States

Marinus Pharmaceuticals, Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the development of innovative therapeutics for the treatment of seizure disorders, including rare genetic epilepsies and status epilepticus, which includes the use of ZTALMY (ganaxolone). Its U.S. Food and Drug Administration (FDA) approved the Company’s new drug application for the use of ZTALMY oral suspension CV for the treatment of seizures associated with Cyclin-dependent Kinase-like 5 (CDKL5) Deficiency Disorder (CDD) in patients two years of age and older. The Company is also developing ganaxolone for the treatment of other rare genetic epilepsies, including Tuberous Sclerosis Complex (TSC) and for the treatment of Refractory Status Epilepticus (RSE). It is developing ganaxolone in formulations for two different routes of administration: intravenous (IV) and oral to maximize therapeutic reach for adult and pediatric patients in acute and chronic care settings.

Contact Information

Headquarters

5 Radnor Corporate Center Suite 500 100 Matsonford RdRADNOR, PA, United States 19087

Phone

484-801-4670

Fax

302-655-5049

Executives

Chairman of the Board, President, Chief Executive Officer

Scott Braunstein

Chief Financial Officer, Chief Operating Officer, Treasurer

Steven Pfanstiel

Senior Vice President, General Counsel, Corporate Secretary

Martha Manning

Chief Medical Officer

Joseph Hulihan

Chief Commercial Officer

Christina Shafer